Any compound that binds to and activates soluble guanylate cyclase (EC 4.6.1.2).
| Member | Definition | Class |
|---|
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | A member of the class of indazoles that is 1H-indazole which is substituted by a benzyl group at position 1 and a 5-(hydroxymethyl)-2-furyl group at position 3. It is an activator of soluble guanylate cyclase and inhibits platelet aggregation. | [5-[1-(phenylmethyl)-3-indazolyl]-2-furanyl]methanol; lificiguat |
| 4-phenyl-3-furoxancarbonitrile | A 1,2,5-oxadiazole substituted by an oxido, cyano and phenyl groups at positions 2, 3 and 4, respectively. It is a vasodilator and inhibitor of platelet aggregation. | 4-phenyl-3-furoxancarbonitrile |
| bay 58-2667 | A benzoic acid that is 4-(aminomethyl)benzoic acid in which the amino group is substituted by 4-carboxybutyl and 2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl groups. It is a soluble guanylate cyclase activator, used for the treatment of acute decompensated heart failure. | cinaciguat |
| bay 60-4552 | A member of the class of pyrazolopyridines that is 1H-pyrazolo[3,4-b]pyridine which is substituted by a 2-fluorobenzyl and 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl groups at positions 1 and 3, respectively. It is an active metabolite of riociguat and a soluble guanylate cyclase stimulator developed by Bayer for the treatment of erectile dysfunction and heart failure. | nelociguat |
| bay 63-2521 | A carbamate ester that is the methyl ester of {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamic acid. It is used for treatment of chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension | riociguat |
| praliciguat | A member of the class of pyrazoles that is 5-fluoro-2-(1H-pyrazol-3-yl)pyrimidine which is substituted by a 2-fluorobenzyl group at position 1, 1,2-oxazol-3-yl group at position 5, and by a [3,3,3-trifluoro-2-hydroxy-2-(trifluoromethyl)propyl]nitrilo group at position 4. It is a soluble guanylate cyclase stimulator under clinical development for the treatment of heart failure with preserved ejection fraction. | praliciguat |
| vericiguat | A pyrazolopyridine that is 5-fluoro-1H-pyrazolo[3,4-b]pyridine in which the amino hydrogen at position 1 has been substituted by a 2-fluorobenzyl group and the hydrogen at position 3 has been substituted by a 4,6-diamino-5-[(methoxycarbonyl)amino]pyrimidin-2-yl group. It is a soluble guanylate cyclase stimulator which is used for treatment of chronic heart failure. | vericiguat |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 24.5313 | 1 | 4 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 22.8518 | 1 | 3 |
| arylsulfatase A | Homo sapiens (human) | Potency | 10.6910 | 1 | 1 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 13.0762 | 2 | 2 |
| Ataxin-2 | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 11.9955 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 23.2809 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 14.4326 | 2 | 4 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 23.1358 | 2 | 4 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 42.2395 | 1 | 2 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 2 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.1585 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 32.4648 | 2 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 23.9185 | 1 | 1 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 16.9330 | 1 | 1 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 2 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 2 | 4 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 100.0000 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 3.2254 | 1 | 2 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 10.7372 | 3 | 3 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.0286 | 2 | 5 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 8.8140 | 4 | 4 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 37.2212 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 23.9185 | 1 | 1 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.5893 | 1 | 2 |
| geminin | Homo sapiens (human) | Potency | 12.3889 | 2 | 3 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 1.4125 | 1 | 1 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 29.0212 | 2 | 5 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 23.9185 | 1 | 1 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 12.5893 | 2 | 2 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 23.9185 | 1 | 2 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 28.3708 | 1 | 2 |
| Interferon beta | Homo sapiens (human) | Potency | 23.9185 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 14.5874 | 2 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 31.4024 | 1 | 2 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 24.3787 | 2 | 4 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 0.0050 | 1 | 1 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 10.2693 | 2 | 3 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 9.4562 | 2 | 4 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 56.2341 | 1 | 1 |
| NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 184.1262 | 1 | 2 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 34.0322 | 1 | 2 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 9.6560 | 2 | 2 |
| polyprotein | Zika virus | Potency | 37.2212 | 1 | 1 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| ras-related protein Rab-9A | Homo sapiens (human) | Potency | 42.3286 | 1 | 3 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 23.7781 | 1 | 1 |
| Smad3 | Homo sapiens (human) | Potency | 10.9812 | 3 | 3 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.3388 | 1 | 3 |
| TDP1 protein | Homo sapiens (human) | Potency | 14.5015 | 2 | 2 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 50.1187 | 1 | 1 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 24.9320 | 4 | 8 |
| Thrombopoietin | Homo sapiens (human) | Potency | 3.9811 | 2 | 2 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 56.2341 | 1 | 1 |